Study of Amivantamab, a Human Bispecific EGFR and cMet Antibody, in Participants With Advanced Non-Small Cell Lung Cancer (NCT02609776)
A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of JNJ-61186372, a Human Bispecific EGFR and cMet Antibody, in Subjects With Advanced Non-Small Cell Lung Cancer
🩺 Plain-English Summary (8th-Grade Level)
The purpose of study is to evaluate the safety, pharmacokinetics, and preliminary efficacy of Amivantamab as a monotherapy and in combination with lazertinib, and to determine the recommended Phase 2 dose (RP2D) (monotherapy), recommended Phase 2 combination dose (RP2CD) (combination therapy), and to determine recommended Phase 2 Dose (RP2q3W) with combination chemotherapy (Amivantamab in combination with standard of care carboplatin and pemetrexed) in 21 day treatment cycle for participants with advanced non-small cell lung cancer (NSCLC).
Who can join: Review the eligibility criteria below.
Location: Clinical Research Facility — Duarte, California
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (69 Sites)
Showing the first 25 of 69 sites.
- Clinical Research Facility — Duarte, California
- Clinical Research Facility — La Jolla, California
- Clinical Research Facility — Orange, California
- Clinical Research Facility — Santa Monica, California
- Clinical Research Facility — West Hollywood, California
- Clinical Research Facility — Tampa, Florida
- Clinical Research Facility — Chicago, Illinois
- Clinical Research Facility — Bethesda, Maryland
- Clinical Research Facility — Boston, Massachusetts
- Clinical Research Facility — Detroit, Michigan
- Clinical Research Facility — Rochester, Minnesota
- Clinical Research Facility — St Louis, Missouri
- Clinical Research Facility — New York, New York
- Clinical Research Facility — Portland, Oregon
- Clinical Research Facility — Philadelphia, Pennsylvania
- Clinical Research Facility — Houston, Texas
- Clinical Research Facility — Fairfax, Virginia
- Clinical Research Facility — Camperdown,
- Clinical Research Facility — Heidelberg,
- Clinical Research Facility — Kogarah,
- Clinical Research Facility — Murdoch,
- Clinical Research Facility — Woolloongabba,
- Clinical Research Facility — Toronto, Ontario
- Clinical Research Facility — Beijing,
- Clinical Research Facility — Changchun,
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Non-Small-Cell Lung Cancer
- Lorlatinib Continuation Study — Irvine, California
- Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations — Fullerton, California
Explore by condition: All Non-Small-Cell Lung Cancer clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.